A groundbreaking clinical trial led by Australian researchers is creating waves in the world of precision oncology. The Australian National University (ANU), in collaboration with Canberra Health Services and biotech firm Pimera Therapeutics, has launched a pioneering study targeting aggressive cancers driven by the elusive MYC protein – implicated in up to 70% of human cancers.
This innovative trial uses a "basket" approach where participants are grouped based on shared molecular biomarkers instead of cancer type. By focusing on disrupting the cellular processes triggered by MYC, the experimental drug PMR-116 works to inhibit ribosomal biogenesis, a process exploited by these tumors. Early results have sparked optimism among experts.
ANU professor Mark Polizzotto, who is leading the trial, noted, "MYC has long been considered 'undruggable,' but early results of PMR-116 show promise in changing that perception." The study will enroll patients at major hospitals in Canberra, Melbourne, and Sydney starting in late 2025, prioritizing those with cancers resistant to standard therapies.
Co-developer ANU professor Ross Hannan emphasized that this approach marks a fresh direction in precision oncology—targeting cancer's molecular drivers over its location. If successful, this trial could redefine treatment paradigms globally and bring new hope to patients facing the toughest diagnoses. Stay tuned for more updates on this exciting development! 🚀
Reference(s):
Researchers launch pioneering trial targeting untreatable cancers
cgtn.com
